The following are the known, listed and published adverse drug ev...

The following are the known, listed and published adverse drug events associated with fluoroquinolone therapy. Avelox is a chemotherapuetic antibiotic belonging to this class: Adverse effects related to fluoroquinolones Asthenia Edema Fever Malaise Rigors Substernal Chest Pain Syncope Cardiovascular Disorders Cardiac Failure Circulatory Failure Hypertension Central and Peripheral Nervous System Disorders Abnormal Coordination Coma Convulsions Seizures Hyperkinesia Hypertonia Hypoaesthesia Involuntary Muscle Contractions Paresthesia Paralysis Speech Disorders Stupor Tremor Vertigo Gastrointestinal System Disorders Dry Mouth Dysphagia Gastroenteritis G.I.Hemorrhage Pancreatitis Pseudomembranous Colitis Tongue Edema Hearing and Vestibular Disorders Ear Disorders Tinnitus Heart Rate and Rhythm Disorders Arrhythmia Atrial Fibrillation Bradycardia Cardiac Arrest Heart Block Palpitation Supraventricular Tachycardia Tachycardia Ventricular Fibrillation Hematology Decreased Lymphocytes Liver and Biliary System Disorders Abnormal Hepatic Function Cholelithiasis Hepatic Coma Jaundice Metabolic and Nutritional Disorders Aggravated Diabetes Mellitus Decreased Glucose Decreased Magnesium Increased Calcium Dehydration Hyperglycemia Hyperkalemia Hypoglycemia Hypokalemia Increased LDH Weight Loss Musculo-Skeletal System Disorders Arthralgia Arthritis Arthrosis Muscle Weakness Myalgia Osteromyelitis Rhabdomyolysis Synovitis Tendinitis Myo, Endo, Pericardial and Valve Disorders Angina Pectoris Coronary Thrombosis Myocardial Infarction Neoplasms Carcinoma Parosmia Platelet, Bleeding and Clotting Disorders Abnormal Platelets Embolism Epistaxis Purpura Thrombocytopenia Psychiatric Disorders Abnormal Dreaming Aggressive Reaction Agitation Anorexia Anxiety Confusion Delirium Depression Emotional Liability Hallucination Impaired Concentration Impotence Manic Reaction Mental Deficiency Nervousness Paranoia Sleep Disorders Somnolence Withdrawal Syndrome Suicide Red Blood Cell Disorders Anemia Reproductive Disorders Ejaculation Failure Resistance Mechanism Disorders Fungal Infections Genital Moniliasis Respiratory System Disorders ARDS Asthma Coughing Dyspnea Haemoptysis Hypoxia Pleural Effusion Respiratory Insufficiency Respiratory Failure Skin and Appendages Disorders Erythema Nodosum Genital Pruritus Increased Sweating Skin Disorders Skin Exfoliation Skin Ulceration Urticaria Urinary System Disorders Abnormal Renal Function Acute Renal Failure Face Edema Crystalluria Cylindruria Hematuria Vascular (Extracardiac) Disorders Cerebrovascular Disorder Phlebitis Vision Disorders Abnormal Vision Conjunctivitis Diplopia Retina Damage Cornea Damage Ophthalmologic Abnormalities Cataracts Multiple Punctate Lenticular Opacities White Cell and RES Disorders Granulocytopenia Leukocytosis Leukopenia Lymphadenopathy WBC Abnormal Count Allergic Pneumonitis Anaphylactic Shock Anaphylactoid Reaction Dysphonia Abnormal EEG Encephalopathy Eosinophilia Erythema Multiforme Hemolytic Anemia Multi System Organ Failure (Death) Increased International Normalized Ratio (INR) Prothrombin Time Stevens-Johnson Syndrome Tendon Rupture Torsades de Pointes Vasodilation This is but a small sampling of various adverse reactions associated with such therapy. This list goes on and on and on and on and on. The physician has no clue as to what these drugs can and will do to a patient. There is no known treatment for a majority of the severe reactions. Such reactions DO NOT abate once therapy is discontinued in a subset of those so treated and the current research indicates that such events are to be considered permanent in nature. David T Fuller Director Fluoroquinolone Toxicity Research Foundation davidtfull@aol.com www.fqresearch.org